Rex Medical, L.P. v. Intuitive Surgical, Inc.

District Court, D. Delaware·Decided May 5, 2020·No. 1:19-cv-00005·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

REX MEDICAL, L.P., ) ) Plaintiff, ) ) v. ) C.A. No. 19-005 (MN) ) INTUITIVE SURGICAL, INC., ) INTUITIVE SURGICAL OPERATIONS, ) INC. and INTUITIVE SURGICAL ) HOLDINGS, LLC, ) ) Defendants. )

MEMORANDUM ORDER

At Wilmington this 5th day of May 2020: As announced at the hearing on April 24, 2020, IT IS HEREBY ORDERED that the disputed claim terms of U.S. Patent No. 9,439,650 (“the ’650 patent”) are construed as follows: 1. “the beam is configured to engage the first and second jaws one of entirely or substantially from within” shall have its ordinary meaning, with the understanding that “from within” means at least partially within (claim 5);

2. “staple pusher” means “a component that presses against a staple” with the clarification that it need not directly touch the staple (claims 4, 6, 21);

3. “at least one of the lower portion or the upper portion configured to cause the staple pusher to move a staple” means “at least one of the lower portion or the upper portion is designed, constructed or set up to cause the staple pusher to move a staple” (claim 6); and

4. “at least a portion of the first jaw and the second jaw is curved” means “at least a portion of the first jaw and the second jaw forms an arc” with the clarification that the arc need not be along the longitudinal axis (claim 12).

In addition, for the reasons set forth below: 1. “at least one of a gear and a cable operatively coupled to at least one of the first jaw and the second jaw and configured to move at least one of the first jaw and the second jaw from the first configuration to the second configuration” means “at least one of a gear or a cable operatively coupled to at least one of the first jaw or the second jaw and configured to move at least one of the first jaw or the second jaw from the first configuration to the second configuration” (claim 4);

The parties briefed the issues (see D.I. 63), submitted an appendix containing both intrinsic and extrinsic evidence (see D.I. 64), including expert declarations1 (see id., Exhibits D, EE, GG, LL), and provided a tutorial describing the relevant technology2 (see D.I. 62). The Court carefully reviewed all submissions in connection with the parties’ contentions regarding the disputed claim terms, heard oral argument (see D.I. 75), and applied the following legal standards in reaching its decision: I. LEGAL STANDARDS A. Claim Construction “[T]he ultimate question of the proper construction of the patent [is] a question of law,” although subsidiary fact-finding is sometimes necessary. Teva Pharms. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831, 837-38 (2015). “[T]he words of a claim are generally given their ordinary and customary meaning [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc) (internal

1 Plaintiff Rex Medical, L.P. (“Plaintiff” or “Rex”) submitted declarations from Michael Dolgin, Ph.D., owner and principal consultant of M. Dolgin Consulting, a medical technology design and development firm, with 49 years of experience (D.I. 64, Exhibit GG) and Albert Juergens, III, an engineering and patent consultant at OST Corporation with over 35 years of experience (Id., Exhibit LL). Defendants Intuitive Surgical, Inc., Intuitive Surgical Operations, Inc. and Intuitive Surgical Holdings, LLC (collectivenly, “Defendants” or “Intuitive”) submitted declarations from Robert D. Howe, Ph.D., the Abbott and James Lawrence Professor of Engineering at the Harvard School of Engineering and Applied Sciences. (Id., Exhibits D, EE).

2 The above-mentioned tutorial was submitted by Intuitive. Rex did not submit a tutorial. citations and quotation marks omitted). Although “the claims themselves provide substantial guidance as to the meaning of particular claim terms,” the context of the surrounding words of the claim also must be considered. Id. at 1314. “[T]he ordinary meaning of a claim term is its meaning to the ordinary artisan after reading the entire patent.” Id. at 1321 (internal quotation marks

omitted). The patent specification “is always highly relevant to the claim construction analysis . . . [as] it is the single best guide to the meaning of a disputed term.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). It is also possible that “the specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor’s lexicography governs.” Phillips, 415 F.3d at 1316. “Even when the specification describes only a single embodiment, [however,] the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction.” Hill-Rom Servs., Inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (internal quotation marks

omitted) (quoting Liebel-Flarsheim Co. v. Medrad, Inc., 358 F.3d 898, 906 (Fed. Cir. 2004)). In addition to the specification, a court “should also consider the patent’s prosecution history, if it is in evidence.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995) (en banc), aff’d, 517 U.S. 370 (1996). The prosecution history, which is “intrinsic evidence, . . . consists of the complete record of the proceedings before the PTO [Patent and Trademark Office] and includes the prior art cited during the examination of the patent.” Phillips, 415 F.3d at 1317. “[T]he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the course of prosecution, making the claim scope narrower than it would otherwise be.” Id. In some cases, courts “will need to look beyond the patent’s intrinsic evidence and to consult extrinsic evidence in order to understand, for example, the background science or the

Free access — add to your briefcase to read the full text and ask questions with AI

Rex Medical, L.P. v. Intuitive Surgical, Inc., (D. Del. 2020).

Rex Medical, L.P. v. Intuitive Surgical, Inc. (Rex Medical, L.P. v. Intuitive Surgical, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
535 U.S. 722 (Supreme Court, 2002)
Merck & Co. v. Teva Pharmaceuticals USA, Inc.
395 F.3d 1364 (Federal Circuit, 2005)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
Technology Licensing Corp. v. Videotek, Inc.
545 F.3d 1316 (Federal Circuit, 2008)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Hill-Rom Services, Inc. v. Stryker Corporation
755 F.3d 1367 (Federal Circuit, 2014)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
789 F.3d 1335 (Federal Circuit, 2015)
Ethicon Endo-Surgery, Inc. v. Covidien, Inc.
796 F.3d 1312 (Federal Circuit, 2015)
Simo Holdings Inc. v. Hong Kong Ucloudlink Network Tech. Ltd.
376 F. Supp. 3d 369 (S.D. Illinois, 2019)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)